Skip to content

Clinical Study of Modified Liqi Tongbian Formula for the Treatment of Cathartic Colon

Clinical study and mechanism of modified Liqi Tongbian Decoction in the treatment of cathartic colon based on the "gut microbiota/5-HT/enteric neurons" axis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000518
Enrollment
Unknown
Registered
2026-03-13
Start date
2025-03-18
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cathartic Colon

Interventions

Chinese Medicine Treatment Group:Oral administration of Modified Qi-Regulating and Stool-Loosening Formula
Western medicine group:Oral Prucalopride Tablets

Sponsors

The Second People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Case Group (1) Meets the above-mentioned TCM and Western medicine diagnostic criteria for CC; (2) Male or female, aged 18–75 years; (3) No use of antibiotics, probiotics, or medications that may cause constipation within the past 3 months; (4) Agrees to participate in the study and signs the informed consent form; (5) Able to cooperate with treatment, participate in medical history inquiries, and complete relevant rating scales. Normal Control Group (1) No history of constipation or other relevant diseases; (2) Male or female, aged 18–75 years; (3) No use of antibiotics, probiotics, or medications that may cause constipation within the past 3 months; (4) Agrees to participate in the study and signs the informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion Criteria for Both Case Group and Normal Control Group (1) Individuals with severe primary or secondary cardiovascular, cerebrovascular, renal, or other systemic diseases, metabolic disorders such as diabetes or hyperthyroidism, or psychiatric conditions; (2) Individuals diagnosed with intestinal tumors via electronic colonoscopy; (3) Individuals meeting the diagnostic criteria for constipation-predominant irritable bowel syndrome; (4) Individuals on long-term use of medications known to cause constipation; (5) Pregnant or lactating women; (6) Those with communication or cognitive impairments.

Design outcomes

Primary

MeasureTime frame
Complete Spontaneous Bowel Movements, CSBM;

Secondary

MeasureTime frame
Fecal consistency score;Score for the degree of difficulty in defecation;Quality of Life Assessment Scale for Constipation Patients;TCM Syndrome Scoring Table;Intestinal flora detection and short-chain fatty acid detection;Elisa method for detecting 5-HT, Ach and NE in serum;

Countries

China

Contacts

Public ContactCuili Lin

The Second People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine

lincuili88@163.com17805935284

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026